The choice of treatment between anti-EGFR and anti-VEGF is based on several aspects, such as RAS/BRAF status (see above), primary tumour site (left vs. right) and the suitability of bevacizumab treatment [52]. This evidence concerns the gene VEGFA and neoplasm.